NCT03576131 - GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2018

Primary Completion Date

October 12, 2021

Study Completion Date

October 12, 2021

Conditions

Colorectal CancerNon-small Cell Lung CancerTriple Negative Breast CancerRenal Cell CarcinomaGastric CancerPancreatic CancerUrothelial Cancer

Interventions

BIOLOGICAL

GEN1029 (HexaBody®-DR5/DR5)

GEN1029 will be administered intravenously. The dose levels will be determined by the starting dose and the escalation steps taken in the trial.

Trial Locations (6)

UT M.D Anderson Cancer Center, Houston

Yale University, New Haven

Hospital Univeritario Vall d'Hebron, Barcelona

START Madrid CIOCC, Madrid

The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle

The Royal Mardsen NHS Foundation Trust, Sutton